Greatview Aseptic Packaging Company Limited (“GAPACK”) confirmed the conclusion of its second-stage independent investigation into the company’s earlier restructuring matters. The Independent Investigator finalised electronic data recovery—including deletion analysis—and conducted additional interviews with former and current management, directors and selected external parties.
Based on these procedures, the Special Investigation Committee stated that all practicable outstanding issues identified during the first-stage investigation have now been addressed, marking the formal completion of the second-stage probe.
Despite this milestone, GAPACK shares have remained suspended since 9:00 a.m. on 19 February 2025 and will continue to be so until further notice. The company will issue further announcements should circumstances change.
Previous disclosures relevant to the investigation include announcements dated 16 May 2025 (Resumption Guidance), 2 October 2025 (first-stage findings), 20 November 2025 (change of investigator) and 15 January 2026 (second-stage findings).
The board currently comprises two executive directors, five non-executive directors and four independent non-executive directors, with Chairman Yuan Xunjun serving as Executive Director.
Comments